ClinicalPercutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure
Introduction
Transcatheter MV repair (TMVR) with MitraClip® (Abbott Vascular, Santa Clara, USA) has become a minimally invasive alternative therapy for patients with MR deemed either non-candidates or at high risk for conventional surgery [1]. TMVR has proved to effectively decrease MR, thus reducing volume overload [2], which leads to inverse remodeling in left cardiac chambers [3]. These changes have been related to improved clinical status and quality of life [4]. Furthermore, different observational series have pointed out a reduction in all-cause mortality in patients who underwent TMVR compared to those treated conservatively [5]. Nevertheless, two recent randomized controlled trials (RCT) [6,7] including only patients with FMR have shown conflicting results.
Our aim was to conduct a meta-analysis to compare survival outcomes between TMVR with MitraClip® system over optimal medical therapy (OMT) versus conservative stand-alone OMT in patients with symptomatic FMR not considered candidates for MV surgery.
Section snippets
Methods
The PRISMA [8] Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and the MOOSE [9] statement for reporting systematic reviews and meta-analyses of observational studies were applied.
Literature search
The search strategy identified a total of 858 potential articles (Fig. 1). Duplicates, articles that did not meet inclusion criteria based on title or abstract, conference abstracts, and narrative or systematic reviews were removed. Thirteen reports were deeply evaluated for eligibility. Ultimately, five studies, two RCT [6,7] and three observational [[12], [13], [14]] series satisfied all inclusion criteria and were used in the qualitative appraisal and quantitative data extraction. Overall,
Discussion
We performed a meta-analysis of all the available evidence to address potential survival benefit of TMVR with MitraClip® device versus conservative stand-alone OMT in patients with FMR. Overall, more than fifteen hundred patients were analyzed within 2 RCT and 3 observational studies. The main finding of our study was a significant reduction in all-cause mortality, consistently beyond 1-year follow up. Furthermore, TMVR was related to a reduction in the incidence of HF hospitalizations and the
Conclusions
TMVR with MitraClip® system was related to a significant reduction in all-cause mortality, hospitalizations for HF and the need for HF transplant, left ventricular assist device or unplanned surgery. Differences in survival become significantly apparent beyond 1-year follow up. Given the heterogeneity in the enrolling criteria of included studies, these results support the use of the recommendations of the American Society of Echocardiography for defining severe FMR in patients evaluated for
Funding
This study was supported by a research grant (PdH) in interventional cardiology of the Spanish Society of Cardiology.
Declaration of Competing Interest
Dr. Estevez-Loureiro is proctor for MitraClip® and consultant for Abbott Vascular. The rest of authors have nothing to disclose.
References (32)
- et al.
Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) high risk study
J Am Coll Cardiol
(2012) - et al.
The acute hemodynamic effects of MitraClip® therapy
J Am Coll Cardiol
(2011) - et al.
Comparison of percutaneous mitral valve repair versus conservative treatment in severe functional mitral regurgitation
Am J Cardiol
(2016) - et al.
Real-world cost effectiveness of MitraClip® combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation
Int J Cardiol
(2016) - et al.
2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology Heart Association task force on practice guidelines
J Am Coll Cardiol
(2014) - et al.
Chronic ischemic mitral regurgitation: repair, replace or rethink?
Ann Thorac Surg
(2006) - et al.
Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy. The InSync ICD (Implantable Cardioverter-Defibrillator) Italian registry
J Am Coll Cardiol
(2008) - et al.
Rehospitalization for heart failure: problems and perspectives
J Am Coll Cardiol
(2013) - et al.
Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance
J Am Soc Echocardiogr
(2017) - et al.
Impact of transcatheter mitral valve repair on left ventricular remodeling in secondary mitral regurgitation: a meta-analysis
Struct Hear
(August 2018)
Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review
Clin Res Cardiol
Survival advantage of MitraClip® over medical treatment in patients with mitral regurgitation: a meta-analysis
J Heart Valve Dis
Percutaneous repair or medical treatment for secondary mitral regurgitation
N Engl J Med
Transcatheter mitral-valve repair in patients with heart failure
N Engl J Med
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Ann Intern Med
Cited by (12)
Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Analysis
2023, American Journal of CardiologyPercutaneous repair of systemic atrioventricular valve regurgitation with the MitraClip-NT system in congenitally corrected transposition of great arteries
2022, Journal of Cardiology CasesCitation Excerpt :The etiology of SAVV regurgitation in patients with CCTGA is leaflet tethering due to systemic ventricle dilatation and SAVV annular dilatation. In patients with functional MR, transcatheter mitral repair using the MitraClip system is an ideal treatment for symptomatic heart failure under optimal medical therapy [9]. According to those data, the MitraClip system may be a favorable treatment option for functional severe SAVV regurgitation.
MitraClip or Cardiac Replacement Therapy in Patients with Advanced Heart Failure?
2020, Cardiovascular Revascularization MedicineTo Clip, Or Not To Clip, In Patients With Functional Mitral Regurgitation
2020, Cardiovascular Revascularization MedicineMitraClip or Cardiac Replacement Therapy in Patients with Advanced Heart Failure?
2020, Cardiovascular Revascularization MedicineEDITORIAL: 'Coapting' Clinical Evidence on Mortality Impact of MitraClip Implantation in Patients with Functional Mitral Regurgitation
2020, Cardiovascular Revascularization Medicine